Towards national guidance on dengue and chikungunya vaccination in travellers: Lessons from global recommendations - PubMed
5 hours ago
- #Dengue
- #Vaccination
- #Chikungunya
- Dengue and chikungunya are mosquito-borne viral diseases expanding due to climate change, urbanization, and globalization.
- In 2024, global dengue cases exceeded 14.6 million with over 12,000 deaths, while chikungunya cases surpassed 410,000 in the Americas.
- Poland reported 126 imported dengue cases and four imported chikungunya cases in 2024.
- Recent vaccine approvals include Qdenga (TAK-003) for dengue and IXCHIQ (VLA1553) for chikungunya, but implementation faces challenges.
- Vaccination recommendations vary among global health authorities, with most restricting Qdenga to travelers with prior dengue infection.
- IXCHIQ use has been limited in several countries due to reports of severe adverse events, including encephalitis and a fatal case.
- Diagnostic limitations, such as flavivirus cross-reactivity, complicate vaccination decisions.
- Tailored recommendations for Poland prioritize vaccination for travelers with prior dengue infection and high exposure risk.
- The framework presented may aid policy development in other non-endemic countries.